1. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
- Author
-
Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, and Briscoe CP
- Subjects
- 3T3-L1 Cells, Adipose Tissue, White drug effects, Adipose Tissue, White metabolism, Aminopyridines pharmacokinetics, Animals, Blood Glucose metabolism, Body Weight drug effects, Cytokines blood, Dietary Fats administration & dosage, Dietary Fats pharmacology, Eating drug effects, Humans, Insulin blood, Insulin pharmacology, Insulin Receptor Substrate Proteins metabolism, Insulin Resistance, JNK Mitogen-Activated Protein Kinases metabolism, Lipopolysaccharides pharmacology, Male, Mice, Mice, Inbred C57BL, Mitogen-Activated Protein Kinase 8 antagonists & inhibitors, Mitogen-Activated Protein Kinase 8 metabolism, Obesity drug therapy, Obesity etiology, Obesity pathology, Phosphorylation drug effects, Protein Kinase Inhibitors pharmacokinetics, Proto-Oncogene Proteins c-jun metabolism, Tumor Necrosis Factor-alpha pharmacology, U937 Cells, Aminopyridines pharmacology, JNK Mitogen-Activated Protein Kinases antagonists & inhibitors, Protein Kinase Inhibitors pharmacology
- Abstract
c-Jun NH(2)-terminal kinase (JNK) plays an important role in insulin resistance; however, identification of pharmacologically potent and selective small molecule JNK inhibitors has been limited. Compound A has a cell IC(50) of 102 nM and is at least 100-fold selective against related kinases and 27-fold selective against glycogen synthase kinase-3beta and cyclin-dependent kinase-2. In C57BL/6 mice, compound A reduced LPS-mediated increases in both plasma cytokine levels and phosphorylated c-Jun in adipose tissue. Treatment of mice fed a high-fat diet with compound A for 3 wk resulted in a 13.1 +/- 1% decrease in body weight and a 9.3 +/- 1.5% decrease in body fat, compared with a 6.6 +/- 2.1% increase in body weight and a 6.7 +/- 2.1% increase in body fat in vehicle-treated mice. Mice pair fed to those that received compound A exhibited a body weight decrease of 7 +/- 1% and a decrease in body fat of 1.6 +/- 1.3%, suggesting that reductions in food intake could not account solely for the reductions in adiposity observed. Compound A dosed at 30 mg/kg for 13 days in high-fat fed mice resulted in a significant decrease in phosphorylated c-Jun in adipose tissue accompanied by a decrease in weight and reductions in glucose and triglycerides and increases in insulin sensitivity to levels comparable with those in lean control mice. The ability of compound A to reduce the insulin-stimulated phosphorylation of insulin receptor substrate-1 (IRS-1) von Ser307 and partially reverse the free fatty acid inhibition of glucose uptake in 3T3L1 adipocytes, suggests that enhancement of insulin signaling in addition to weight loss may contribute to the effects of compound A on insulin sensitization in vivo. Pharmacological inhibition of JNK using compound A may therefore offer an effective therapy for type 2 diabetes mediated at least in part via weight reduction.
- Published
- 2008
- Full Text
- View/download PDF